Skip to main content
SpringerLink
Log in

Oxaliplatin-Based Chemotherapy for Colon Cancer

  • Chapter
Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1200 Accesses

Abstract

For more than 40 years the treatment of colorectal cancer was based upon the use of 5-fluoruracil (5-FU) administered according to a variety of schedules, either alone or with several modulators. The response rate ranged between 10% and 20% with progression-free survival (PFS) of 6 months and overall survival of around 1 year. The introduction into the clinic of oxaliplatin, a diaminocyclohexane platinum analogue, and the demonstrated synergistic activity when combined with 5-FU, led to the popular scheme FOLFOX 4 and its simplified forms, including more recent evolutions with capecitabine as a substitute for leucovorin-modulated 5-FU. We learned from several randomised phase III trials that in the advanced setting these combinations could produce a response rate ranging from 37 to 50% with a progression-free survival of around 8– months. Furthermore, a small percentage of unselected patients initially considered inoperable may become resectable following chemotherapy. Oxaliplatin-based regimens can be further strengthened by the addition of a third component, either a traditional drug such as CPT11 or a targeted agent such as the anti VEGF antibody bevacizumab and the anti-EGFR receptor cetuximab. The sequential administration of all these active agents significantly improved the outcome of advanced colorectal cancer patients with several studies reporting median survivals exceeding 20 months. Two large phase III studies (the MOSAIC trial and the NSABP C07) enrolling patients with stage II and III colon cancer have consistently demonstrated a 5% absolute improvement in a 3-year DFS favouring the oxaliplatin-containing arms. In the MOSAIC trial the improved 3-year DFS translates in a statistically significant better 6-year survival only for stage III patients (73% vs. 68.6%).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553–60.

    Article  PubMed  CAS  Google Scholar 

  2. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer —a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368–81.

    PubMed  CAS  Google Scholar 

  3. De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499–1503.

    Article  PubMed  Google Scholar 

  4. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–15.

    PubMed  Google Scholar 

  5. Andre T, Louvet C, Raymond E, Tiurnigand C, De Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251–3.

    Article  PubMed  CAS  Google Scholar 

  6. Scheithauer W; Rosen H, Kornek G-V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752–5.

    Article  PubMed  CAS  Google Scholar 

  7. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 1992;10:904–11.

    Google Scholar 

  8. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluoruracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896–903.

    Google Scholar 

  9. Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960–9.

    Google Scholar 

  10. O'Connel MJ, Laurie JA, Kahn M, et al. Prospectively randomised trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295–300.

    Google Scholar 

  11. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluoruracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553–9.

    PubMed  CAS  Google Scholar 

  12. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000;355:1588–96.

    Article  Google Scholar 

  13. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacoter 2004;5:2159–70.

    Article  CAS  Google Scholar 

  14. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059–69.

    Article  PubMed  CAS  Google Scholar 

  15. Yeh KH, Cheng AL, Wan JP, Lin CS, Liu CC. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 2004;15:71–6.

    Article  Google Scholar 

  16. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.

    PubMed  Google Scholar 

  17. Saltz LB, Cox J V, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–13.

    Article  PubMed  CAS  Google Scholar 

  18. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7.

    Article  PubMed  CAS  Google Scholar 

  19. Tournigand C, Andrè T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 2004:22: 229–37.

    Article  PubMed  CAS  Google Scholar 

  20. Goldberg RM, Sargent D, Morton RF, et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.

    Article  PubMed  CAS  Google Scholar 

  21. Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus high-dose folinic acid and 5-fluo rouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy cooperative group phase III trial. Ann Oncol 2005;16:878–86.

    Article  PubMed  CAS  Google Scholar 

  22. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005;16:869–77.

    Article  PubMed  CAS  Google Scholar 

  23. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomised trial of FOLFIRI versus FOFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol 2005;23:4866–75.

    Article  PubMed  CAS  Google Scholar 

  24. Rothenberg ML, Meropol NJ, Poplin A, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801–7.

    PubMed  CAS  Google Scholar 

  25. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced color-ectal cancer improves with availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14.

    Article  PubMed  CAS  Google Scholar 

  26. Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxali-platin plus continuous infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002;20:2651–7.

    Article  PubMed  CAS  Google Scholar 

  27. Comella P, Casaretti R, De Rosa V, et al. Oxaliplatin plus irinotecan and leucovorin- modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 2002;13:1874–81.

    Article  PubMed  CAS  Google Scholar 

  28. Calvo E, Cortes J, Rodriguez J, et al. Irinotecan, oxaliplatin, and 5-fluorouracil/ leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002;2:104–10.

    Article  PubMed  CAS  Google Scholar 

  29. Calvo E, Cortes J, Gonzalez-Cao M, et al. Combined irinotecan, oxaliplatin, and 5- fluorouracil in patients with advanced colorecatl cancer: a feasibility pilot study. Oncology 2002;63:254–65.

    Article  PubMed  CAS  Google Scholar 

  30. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;19:4006–14.

    Article  Google Scholar 

  31. Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14:481–9.

    Article  PubMed  CAS  Google Scholar 

  32. Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003;20:3761–9.

    Article  Google Scholar 

  33. Cals L, Rixe O, Francois E, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluoruracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer. Ann Oncol 2004;15:1018–24.

    Article  PubMed  CAS  Google Scholar 

  34. Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15:1766–72.

    Article  PubMed  CAS  Google Scholar 

  35. Seium Y, Stupp R, Rushtaller T, et al. Oxaliplatin combined with irinotecan and 5- fluorouracil/ -leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol 2005;16: 762–6.

    Article  PubMed  CAS  Google Scholar 

  36. Bonetti A, Zaninelli M, Durante E, et al. Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT11) in advanced, 5-FU refractory, colorectal cancer: MTD definition and efficacy evaluation. A phase I–II study. Tumori 2006;92:389–95.

    PubMed  CAS  Google Scholar 

  37. Souglakos A, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research group (HORG). Br J Cancer 2007;94:798–805.

    Article  Google Scholar 

  38. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluoruracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–6.

    Article  PubMed  CAS  Google Scholar 

  39. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angio-genesis suppresses tumour growth in vivo. Nature 1993;362:841–4.

    Article  PubMed  CAS  Google Scholar 

  40. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–9.

    PubMed  CAS  Google Scholar 

  41. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluoruracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706–12.

    Article  PubMed  CAS  Google Scholar 

  42. Hurwitz H, Feherenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  43. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxali-platin, fluoruracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol 2007;25:1539–44.

    Article  PubMed  CAS  Google Scholar 

  44. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: survival and response results from XELOX-1/NO16966, a randomised phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2007;25:171:4030 (abstract).

    Google Scholar 

  45. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1/NO16966, a randomised phase III trial in first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol 2007;25:170:4028 (abstract).

    Google Scholar 

  46. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinote-can in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.

    Article  PubMed  CAS  Google Scholar 

  47. Diaz Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/ 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proc Am Soc Clin Oncol 2005;23:3535 (abstract).

    Google Scholar 

  48. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxalplatin (FOLFOX 4) versus FOLFOX 4 in the fist-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proc Am Soc Clin Oncol 2007;25:4035 (abstract).

    Google Scholar 

  49. Venook A., Niedzwiecki D., Hollis D. et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 2006;24:3509 (abstract).

    Google Scholar 

  50. CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol. 2006;4:452–3.

    Google Scholar 

  51. PACCE: A randomized, Open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic color-ectal cancer. (Accessed 3 May 2008, at http://www.amgen.com/media/media_pr_detail.jsp? releaseID = 977186– 20 k.)

  52. Andrè T, Boni C, Monudeji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51.

    Article  PubMed  Google Scholar 

  53. Kuebler JP, Wieand S, O'Connel MJ, et al. Oxaliplatin combined with weekly bolus fluorour-acil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198–204.

    Article  PubMed  CAS  Google Scholar 

  54. Ychou M, Raoul JL, Douillard J Y, et al. A phase III randomised trial of LV5FU2 + CPT11 vs LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Proc Am Soc Clin Oncol 2005;23:3502 (abstract).

    Google Scholar 

  55. Saltz L, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456–61.

    Article  PubMed  CAS  Google Scholar 

  56. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomised phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc Am Soc Clin Oncol 2005;23:8 (abstract).

    Google Scholar 

  57. Kuebler JP, Colangelo L, O'Connel MJ, et al. Severe enteropathy among patients with stage II/III colon cancer treated on a randomised trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. A prospective study. Cancer 2007;110:1945–50.

    Article  PubMed  CAS  Google Scholar 

  58. Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23:3311–3.

    Article  PubMed  Google Scholar 

  59. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc Am Soc Clin Oncol 2007;25:4007 (abstract).

    Google Scholar 

  60. Taieb J, Puig PL, Bedenne L. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther 2008;8:183–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Mater Salutis Hospital, Legnago, Italy

    Andrea Bonetti & Furini Lara

Authors
  1. Andrea Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Furini Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology, Mater Salutis Hospital, Legnago, Italy

    Andrea Bonetti

  2. Institute of Pharmacology, University of Verona, Verona, Italy

    Roberto Leone

  3. Division of Medical Oncology, New York University School of Medicine and the NYU Cancer Institute, New York, NY, USA

    Franco M. Muggia

  4. Department of Medicine and the Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA

    Stephen B. Howell

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bonetti, A., Lara, F. (2009). Oxaliplatin-Based Chemotherapy for Colon Cancer. In: Bonetti, A., Leone, R., Muggia, F.M., Howell, S.B. (eds) Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-459-3_31

Download citation

Publish with us

Policies and ethics

Search

Navigation